Immunology

Global Cough, Cold & Allergy (CCA) Treatment Market 2020-2024: Escalating Demand for Antihistamines Nasal Therapy

Retrieved on: 
Thursday, January 7, 2021
Medical specialties, Clinical medicine, Medicine, Immune system, Immunology, Antihistamine, Vasoconstrictors, Cough, Common cold, Allergy

DUBLIN, Jan. 7, 2021 /PRNewswire/ -- The "Global Cough, Cold & Allergy (CCA) Treatment Market (By Product Category, End-Users & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 7, 2021 /PRNewswire/ -- The "Global Cough, Cold & Allergy (CCA) Treatment Market (By Product Category, End-Users & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global cough, cold & allergy (CCA) treatment market is expected to reach US$35.36 billion in 2024, growing at a CAGR of 3.90%, for the duration spanning 2020-2024.
  • A few notable trends may include escalating demand for antihistamines nasal therapy, accelerating growth rates of infectious diseases, increasing focus on telehealth and growth in pharmaceutical & biotech merger & acquisition.
  • The report provides a comprehensive analysis of the global cough, cold & allergy (CCA) treatment market.

Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49

Retrieved on: 
Thursday, January 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Biotechnology, Immunology, Life sciences, Antineoplastic drugs, Antibody-drug conjugate, Asco, Monoclonal antibody

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference.
  • In addition, Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49s clinical progress.
  • The J.P. Morgan presentation will take place on Monday, January 11, 2021 at 3:40 p.m.
  • Zymeworks second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks proprietary ZymeLink linker-cytotoxin.

Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 7, 2021
Branches of biology, Developmental neuroscience, Biology, Proteins, Autoimmunity, Immunology, MuSK protein, Myasthenia gravis, Myasthenia

PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m.

Key Points: 
  • PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m.
  • A live webcast of the presentation will be available on the News and Events section of the companys website at www.cabalettabio.com .
  • Following the presentation, a replay of the webcast will be available on the website for 90 days.
  • The Companys lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

TScan Therapeutics Appoints Brian M. Silver, J.D., to Its Board of Directors

Retrieved on: 
Thursday, January 7, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious diseases, Clinical trials, Life sciences, Branches of biology, Medical specialties, Immunology, Biotechnology, Pharmaceutical industry, Pharmacy, Specialty drugs, Biopharmaceutical, TRA, T-cell receptor, T cell

TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors.

Key Points: 
  • TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors.
  • Mr. Silver is Chief Financial Officer and Head of Corporate Development at Freeline Therapeutics Holdings plc, a clinical-stage systemic gene therapy company.
  • TScan discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases.
  • TScan was co-founded by Board Chair Christoph Westphal (Partner, Longwood Fund) based on pioneering research from the Elledge Lab at Brigham and Womens Hospital.

Proteomic data derived from Immunovia's IMMray™-platform allows differential diagnosis of difficult to distinguish autoimmune diseases

Retrieved on: 
Thursday, January 7, 2021
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Syndromes, Immunology, Autoimmunity, Autoimmune disease, Sjögren syndrome, Rheumatology

Early and correct diagnosis of inflammatory rheumatic diseases is presently a clinical challenge due to the variety of symptoms.

Key Points: 
  • Early and correct diagnosis of inflammatory rheumatic diseases is presently a clinical challenge due to the variety of symptoms.
  • We believe this supports the rationale of using IMMray to reflect the biological complexity of autoimmune diseases."
  • These results suggest that the use of a multiplexed approach such as IMMrayis highly suitable for decoding multifactorial diseases like autoimmune diseases.
  • We will incorporate these signatures and further evaluate them in our discovery program for autoimmune diseases."

Proteomic data derived from Immunovia's IMMray™-platform allows differential diagnosis of difficult to distinguish autoimmune diseases

Retrieved on: 
Thursday, January 7, 2021
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Syndromes, Immunology, Autoimmunity, Autoimmune disease, Sjögren syndrome, Rheumatology

Early and correct diagnosis of inflammatory rheumatic diseases is presently a clinical challenge due to the variety of symptoms.

Key Points: 
  • Early and correct diagnosis of inflammatory rheumatic diseases is presently a clinical challenge due to the variety of symptoms.
  • We believe this supports the rationale of using IMMray to reflect the biological complexity of autoimmune diseases."
  • These results suggest that the use of a multiplexed approach such as IMMrayis highly suitable for decoding multifactorial diseases like autoimmune diseases.
  • We will incorporate these signatures and further evaluate them in our discovery program for autoimmune diseases."

Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones

Retrieved on: 
Thursday, January 7, 2021
Type I hypersensitivity, Medical specialties, Immunology, Atopic dermatitis, Dermatitis, Atopy, Clinical medicine, Essential dermatitis, Sodium hypochlorite washes

We reported positive clinical data for EDP1815 in both atopic dermatitis and a human experimental model of inflammation, showing translation of preclinical results into humans.

Key Points: 
  • We reported positive clinical data for EDP1815 in both atopic dermatitis and a human experimental model of inflammation, showing translation of preclinical results into humans.
  • In parallel, we invested in manufacturing capabilities and supply chain to advance our ability to deliver our products at commercial scale.
  • Atopic dermatitis is the most common chronic skin disease, impacting an estimated 10% of adults and 25% of children globally.
  • Generating initial clinical data on the safety and pharmacology of the Companys next anti-inflammatory product candidate, EDP1867, in atopic dermatitis.

Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Retrieved on: 
Wednesday, January 6, 2021
Adjuvants, Immunologic adjuvant, Immunology

EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021.

Key Points: 
  • EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021.
  • The on demand presentation will be available, beginning Monday, January 11, 2021 at 6:00 a.m. E.T.
  • and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations .
  • Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.

Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer

Retrieved on: 
Wednesday, January 6, 2021
Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, University, Pharmaceutical, Health, Education, Oncology, Medical specialties, Immunology, Clinical medicine, Medicine, Bispecific monoclonal antibody, Monoclonal antibody, Antibody, Xencor, Inc., MD Anderson

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
  • Xencors modular scaffold for engineering bispecific antibodies is the XmAb bispecific Fc domain, which enables the rapid creation of stable antibodies with novel anti-tumor mechanisms of action.
  • MD Anderson will work to identify and develop potential antibodies, collaborating with Xencor to apply its XmAb bispecific technology to create therapeutic candidates.
  • For programs not licensed by Xencor, Xencor will receive a portion of future payments received by MD Anderson.

Daratumumab: A Targeted Therapy (IgG1k Human Monoclonal Antibody) that Targets CD38 - Global Emerging Insight and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 6, 2021
General Health, Pharmaceutical, Health, Health sciences, Clinical medicine, Health care, Orphan drugs, Breakthrough therapy, Daratumumab, Immunology, Antineoplastic drugs, CD38, Monoclonal antibody, Targeted therapy, Therapy

The "DARATUMUMAB - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "DARATUMUMAB - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • "DARATUMUMAB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for AL Amyloidosis in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Daratumumab is a targeted therapy (IgG1k human monoclonal antibody) that targets CD38.